Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
201 results
D1.119 - Anti-Inflammatory Effects of miRNA-Mediated Extracellular Vesicles Derived from Mesenchymal Stem Cells in a Murine Asthma Model
D1.123 - Inhibition of the Interleukin Cytokines using novel Peptide Inhibitors for Allergy and Asthma Treatment
D1.124 - Predictive Factors of Clinical Remission in Severe Eosinophilic Asthma Treated with Benralizumab
D1.125 - Biological therapy in severe asthma: 20 years of experience at the Hospital Universitario de Burgos
D1.129 - Bispecific Antibody Targeting IL-33 and TSLP for Treating Asthma and COPD
D1.131 - TRough levels In plasma of dUpilumab and Mepolizumab in Patients with severe astHma (TRIUMPH)
D1.153 - Protocol for a randomized, 5-arm study to evaluate the combination of omalizumab and allergen immunotherapy in patients with asthma due to house dust mites
D1.159 - The successful resolve of nasal polyps in patient with dupilumab treatment
D1.372 - Potential blood biomarkers of disease activity in patients with chronic spontaneous urticaria
D1.375 - Ciclosporin for omalizumab-refractory CSU in a Paediatric population in Cork University Hospital: a case series
D1.376 - Emerging inmunomodulatory agents for atopic dermatitis
D1.377 - Berotralstat effectively controls a type 2 Hereditary Angioedema patient, refractory to other long-term prophylaxis treatments – Case report
D1.378 - Evaluating the efficacy of dupilumab treatment for atopic dermatitis across geographic areas: A systematic review and meta-regression analysis
D1.379 - AllergoOncology: Generation of Equinized Anti-PD-L1 mAbs with Specific Equine Constant Regions by MOE-PCR Ligation-Independent Cloning (LIC)
D1.380 - Quicker EASI 75 or greater decline of DLQI - is it significant? Comparison of dupilumab treatment among children and adults in two centres in Cracow
D1.383 - Nonimmediate hypersensitivity reaction to Lanadelumab in a patient with Hereditary Angioedema: a case report
D1.384 - Long-term Prophylaxis with Lanadelumab in Hereditary and Acquired Angioedema: A Single-Center Retrospective-Prospective “Real-Life” Analysis
D1.385 - Dupilumab Treatment Effects on Atopic Manifestations in Patients with Inborn Errors of Immunity
D1.386 - Impact of dupilumab on allergen specific immunoglobulin E production
D2.71 - Comprehensive approach to severe bronchial asthma: a case study and the role of biologic therapy
Pagination
First page
First
Previous page
Previous
…
Page
3
Page
4
Page
5
Page
6
Current page
7
Page
8
Page
9
Page
10
Page
11
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download